Key Highlights

  • Becton, Dickinson (NYSE:BDX) reported Q3 fiscal 2026 revenue of $5 billion, up 4.4 percent, beating the estimate by 1.96 percent.
  • Adjusted EPS of $3.23 beat the $3.14 estimate by 2.87 percent.
  • Year-to-date free cash flow reached $1.7 billion, up 45 percent versus the prior year.
  • The company raised full-year fiscal 2026 adjusted EPS guidance to a range of $12.62 to $12.72.

Broad-Based Portfolio Strength Drives the Quarterly Beat

Becton, Dickinson and Company (NYSE:BDX), a global medical technology company that develops, manufactures, and sells medical devices, instrument systems, and reagents used in healthcare settings worldwide, reported third quarter fiscal 2026 revenue that reached $5 billion, up 4.4 percent, with over 90 percent of the portfolio delivering high single-digit growth; adjusted operating margin was 24.9 percent, down 130 basis points year over year due to approximately 110 basis points of tariff impact, and adjusted EPS was $3.23, ahead of expectations, driven by double-digit growth in biologic drug delivery, advanced patient monitoring, and tissue regeneration.

This growth was partially offset by known headwinds concentrated in less than 10 percent of the portfolio, including a difficult prior-year Alaris comparison and vaccine softness in China, both playing out largely as expected. Management expects Alaris to return to growth in fiscal 2027, and vaccine pressure is showing signs of stabilization heading into the new fiscal year.

Raised Guidance Reflects Strong Cash Generation and Capital Returns

The company raised full-year fiscal 2026 guidance, with revenue growth now expected toward the high end of the low single-digit FX-neutral range, with foreign exchange now providing a roughly 100 basis point tailwind, and adjusted EPS guidance raised to a range of $12.62 to $12.72. For fiscal 2027, management indicated preliminary expectations of low single-digit organic revenue growth impacted by the ongoing Alaris headwind, with modest, low single-digit EPS growth supported by pricing actions, buybacks, and favorable platform mix, with formal fiscal 2027 guidance to be provided in November alongside a longer-term investor day.

Year-to-date free cash flow was $1.7 billion, up 45 percent versus the prior year, with $3.1 billion returned to shareholders including $2.3 billion in share repurchases and $0.9 billion in dividends; net leverage stood at approximately 2.9 times, with a long-term target range of 2.5 times, and the company continues to target 90 percent free cash flow conversion over time.

Balancing Alaris and Vaccine Headwinds Against Broad-Based Underlying Growth

The concentration of the company's current headwinds within a relatively narrow portion of the portfolio, less than 10 percent, suggests the broader business remains fundamentally healthy, with more than 90 percent of the portfolio delivering high single-digit growth. Should Alaris return to growth in fiscal 2027 as management anticipates, and vaccine pressure in China continue stabilizing, these currently identified drag factors could shift toward becoming tailwinds in the coming fiscal year.

The substantial 45 percent year-over-year increase in free cash flow provides the company with significant capital flexibility, evident in the scale of shareholder returns already deployed through buybacks and dividends. Continued execution on the target of 90 percent free cash flow conversion, alongside progress toward the 2.5 times long-term leverage target, will likely remain important factors supporting the company's capital allocation flexibility heading into fiscal 2027.

Conclusion

Becton, Dickinson's third quarter results reflect broad-based strength across the vast majority of its portfolio, with the company's known Alaris and China vaccine headwinds playing out largely as expected and management pointing to stabilization or reversal of these pressures heading into fiscal 2027. Whether the anticipated Alaris recovery materializes as guided may be a key factor shaping the company's fiscal 2027 growth trajectory, with formal guidance for that year expected in November. The substantial increase in free cash flow generation underscores the company's improving financial flexibility even amid the currently identified portfolio headwinds.